Asian press release distribution

Press Releases for Thursday, June 24, 2021

IBI Group實現非凡業績年內溢利上升151.5% 20:26 HKT/SGT

IBI Group Delivers Exceptional Results with Net Profit Surging 151.5% 20:25 HKT/SGT

Blockpass Accepted to FCA Regulatory Sandbox for Testing Reusable Identities 20:00 HKT/SGT

31st HKTDC Hong Kong Book Fair opens on 14 July 19:00 HKT/SGT

Pertama Digital makes leap forward with two new investors for its digital bank 18:00 HKT/SGT

Central Global Berhad Makes Two Board Appointments 16:00 HKT/SGT

618黑马诞生！国美零售 "真快乐" DAU激增189.11% 14:17 HKT/SGT

618黑馬誕生！國美零售「真快樂」DAU激增189.11% 14:16 HKT/SGT

"真快乐" 618：日活增长彰显娱乐化转型奏效 14:07 HKT/SGT

「真快樂」618：日活增長彰顯娛樂化轉型奏效 14:06 HKT/SGT

エーザイとバイオジェン、lecanemabがアルツハイマー病治療を対象として米国FDAよりブレイクスルーセラピーに指定 12:00 HKT/SGT

三菱重工サーマルシステムズ、国内向けビル用マルチエアコン新シリーズ「LX5A」を8月に発売 12:00 HKT/SGT

昭和電工、酢酸および酢酸ビニルの国内販売価格改定を発表 11:30 HKT/SGT

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) 11:00 HKT/SGT

MainettiCare成为东京2020奥运会中国香港代表团官方口罩供应商 11:00 HKT/SGT

MainettiCare成為東京2020奧運會中國香港代表團官方口罩供應商 11:00 HKT/SGT

MainettiCare Becomes Official Face Mask Supplier of Hong Kong, China Delegation to Tokyo 2020 Olympic Games 11:00 HKT/SGT

Honda Holds World Premiere of the All-new Civic Hatchback 10:50 HKT/SGT

中國生物科技服務(8037.HK)：細胞治療和精准檢測業務雙輪驅動股東增持彰顯發展信心 10:31 HKT/SGT

SAFEHAMSTERS、新しいDEXとステーキングの利点があるプラネットV.1.0を立ち上げます 10:00 HKT/SGT

エーザイ、抗がん剤「タズベリク(R)錠200mg」について日本においてEZH2遺伝子変異陽性の濾胞性リンパ腫に係る効能効果で製造販売承認を取得 10:00 HKT/SGT

Honda、新型「CIVIC」を世界初公開 10:00 HKT/SGT

Hitachi ABB Power Grids teams up with BW Ideol to take offshore wind power into deeper waters 09:00 HKT/SGT

Members from CERT-PH, DICT, UNODC, Armed Forces of the Philippines to discuss future of a cyber-secure nation at PhilSec 2021 08:00 HKT/SGT

Maps.me 宣布與 Booking.com 建立新的現金返還合作夥伴關係 07:00 HKT/SGT

ACN Search:

CleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575